Royalty Report: Drugs, Cancer, Diagnostic – Collection: 64168


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Disease
  • Technical Know How
  • Therapeutic
  • Pharmaceuticals
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 64168

License Grant
The University grants Licensee an exclusive license under the licensed patent(s) and a nonexclusive right under other technology in the licensed field(s) of use to utilize the technology to make,  have  made, use, import, offer to sell and sell licensed products and perform licensed services in the licensed territory. This Grant shall apply to the Licensee and any affiliated company, except that any affiliated company shall not have the right to sublicense others without the University approval, such approval not to be unreasonably withheld.
License Property
PyL (also known as [18F]DCFPyL) is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer.

Technology means the licensed patent(s), data, know how, manufacturing  techniques,  and  any  other  information  or  material  provided  by University  to Licensee.  Technology may or may not be confidential in nature.  Patent(s) – entitled 'PSMA-binding agents and uses thereof'.  Know-how consists of two broad but diverse areas (a) the efficient synthesis of [18F]DCFPyL  (b) clinical implementation with a view to completion of a phase II trial.

Field of Use
PyL is a clinical-stage fluorinated prostate specific membrane antigen ('PSMA')-targeted PET imaging agent for prostate cancer. PyL, when used in conjunction with high-resolution PET imaging, has shown potential for use in identifying prostate cancer.

IPSCIO Record ID: 324838

License Grant
Licensor, a cancer treatment and research institution, grants an exclusive option to take an exclusive world-wide License under Licensed Patents and Technology.

Upon exercise of its option rights, Licensee shall have the exclusive rights in the Territory, with the right to grant sublicenses, to make, have made, use and sell, licensed products utilizing the Licensed Patents and Technology and products utilizing Licensed Technology.

License Property
The patent is titled Prostate-Specific Membrane Antigen.

Gene technology means that part of Licensed technology that pertains to any DNA encoding the prostate specific membrane (PSM) antigen or any portion of the PSM antigen and any DNA, cDNA, and other derivative or portion of said gene that expresses the PSM antigen, including, but not limited to, diagnostic methods employing DNA probes or PCR techniques to detect prostate cancer and gene therapy applications.

Know-how means the skill or ingenuity based upon the body of knowledge and data which comprise all of the methods, processes, designs, engineering information, trade secrets, and other information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees-356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen, Confidential information and Gene technology which Licensor develops, employs in its own activities, or has available for use prior to or during the term of this Agreement.

Licensed technology means information and data relating to prostate specific membrane (PSM) antigen recognized by the monoclonal antibody Licensees -356, any subunits of such antigen, any other monoclonal antibodies or binding proteins or peptides recognizing such antigen and any gene or gene segment encoding for such antigen or portion of such antigen owned by Licensor as of the effective date or acquired during the term of this agreement; including without limitations, inventions, biological materials, computer programs, technical data, apparatus and Know-how, Gene technology and confidential information, whether patentable or unpatentable.

Licensees-356 is a prostate cancer monoclonal antibody conjugate.

Field of Use
The agreement relates to the detection of prostate cancer and gene therapy applications.

The Parties have a development program involving the prostate specific membrane antigen (PSM) and Licensees prostate cancer monoclonal antibody conjugate, -356.

IPSCIO Record ID: 344541

License Grant
University grants an exclusive license, with the right to sublicense, to make, have made, use, have used, import, have imported, offer for sale, have offered for sale, have sold and sell the licensed products in the United States and worldwide under the Patent rights in the Licensed Field.
License Property
The license relates to an invention(s) entitled PSMA Targeted Nanoparticles for Therapy of Prostate Cancer. PSMA is a clinically-validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors.
Field of Use
The Licensed field shall mean all fields.  Licensee is a clinical-stage nanomedicine platform company developing novel targeted and programmable therapeutics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.